|
Twinrix: Combined Hepatitis A and Hepatitis B Vaccine
September 21, 2001
General InformationTwinrix® is a combined hepatitis A and hepatitis B vaccine recently approved by the Food and Drug Administration for persons >18 years. Primary immunization consists of three doses, given on a 0-, 1-, and 6- month schedule, the same schedule as that used for single-antigen hepatitis B vaccine. This means that a person can be fully vaccinated against both hepatitis A and hepatitis B with three injections compared to the five shots needed to complete the series using the single-antigen formulations. Minimum time to complete the hepatitis A and hepatitis B series is the same (see table).Twinrix is indicated for immunization of persons 18 years of age or older against hepatitis A and hepatitis B. Any person in this age group having an indication for both hepatitis A and hepatitis B vaccination can be administered Twinrix, including patients with chronic liver disease, users of illicit injectable drugs, men who have sex with men, and persons with clotting factor disorders who receive therapeutic blood products. For international travel, hepatitis A vaccine is recommended for travelers to areas of high or intermediate hepatitis A endemicity; hepatitis B vaccine is recommended for travelers to areas of high or intermediate hepatitis B endemicity who plan to stay for 6 months and have frequent close contact with the local population.
Evaluating Unlicensed SchedulesThe information below may be helpful to immunization program personnel and clinicians in determining if patients who have received mixed schedules that include Twinrix need further vaccinations to complete the series. In general, it is best to start and finish a series with the same vaccine formulation, using the licensed dosage and schedule. The information below is not intended to serve as a set of alternate schedules for the vaccines.
Acceptable AgesIn the United States, Twinrix is not licensed for persons <18 years old. However, if doses of the U.S. licensed formulation of Twinrix have been inadvertently given to pediatric patients, they may be counted towards completion of the series. A pediatric formulation (Twinrix Junior®) is licensed in other parts of the world, including Canada and Europe. Acceptable complete series for children who have already received dose(s) of Twinrix Junior are described below.
Acceptable Dosing IntervalsFor all of the vaccines in question, the intervals between the first dose and the last dose are critical to eliciting long term protection. Therefore, regardless of the vaccine used, the interval between first dose of hepatitis A antigen and the last dose must be at least 6 months, and the interval between first and last dose of hepatitis B antigen must be at least 4 months.
Mixed SchedulesThe hepatitis A component in Twinrix is formulated with a different dosage and schedule than the single-antigen formulation (see table). The following guidelines are written with the assumption that for any one individual, the impact of having a decreased amount of antigen in one shot of the series (e.g., 720 EL.U. and 1,440 EL.U. of hepatitis A antigen) is probably not large. However, it is important to recognize that this has not been studied directly. Seroconversion rates (percent of persons who develop a protective level of antibody) are very high even after a single-dose of 720 EL.U. of hepatitis A vaccine, but long term protection may be related to the peak concentration of antibody generated by vaccination. The effect on peak antibody concentrations of a 720 EL.U. dose given with a 1,440 EL.U. dose as part of a two-dose series, compared to two 1,440 EL.U. doses, is unknown. The appropriate single-antigen vaccine dosage (pediatric or adult) in a series is determined by the age at the time of each dose.
Acceptable Mixed Schedules for Persons >18 Years OldCombination vaccine followed by single-antigen vaccine(s):
Single-antigen vaccine(s) followed by combination vaccine:
See above section for acceptable dosing intervals.
Acceptable Mixed Schedules for Persons Who Are 18 Years OldCombination vaccine followed by single-antigen vaccines:
Single-antigen pediatric vaccines followed by combination vaccine:
See above section for acceptable dosing intervals.
Mixed Schedules that Include Dose(s) of Twinrix JuniorTwinrix Junior is not licensed in the United States, as of September 30, 2001. Twinrix Junior is a combined hepatitis A and hepatitis B vaccine used in several other countries for persons <18 years. Primary immunization consists of three doses, given on a 0-, 1-, and 6- month schedule, the same schedule as that used for single-antigen hepatitis B vaccine. Twinrix Junior contains 360 EL.U. of hepatitis A antigen and 10 micrograms of hepatitis B antigen. Twinrix Junior is formulated with a different dosage and schedule than the single-antigen pediatric hepatitis A vaccine. The issues about a decreased amount of antigen in 1 dose in mixed schedules that include Twinrix (see Mixed Schedules above) also apply for Twinrix Junior.Twinrix Junior can count towards the hepatitis B series for persons who are <19 years old, because the combination vaccine contains the same dosage of hepatitis B antigen as the pediatric Engerix B. If Twinrix Junior is given to a person >19 years old, it does not count toward any series. The guidelines below provide information that may be helpful to immunization program personnel and clinicians in determining if patients who have received mixed schedules that include Twinrix Junior need further vaccinations to complete the series.
Acceptable Mixed Schedules for Persons <18 Years OldCombination vaccine Twinrix Junior followed by single-antigen vaccine(s):
Acceptable Mixed Schedules for Persons Who Are 18 Years OldCombination vaccine Twinrix Junior followed by single-antigen vaccine(s):
Combination vaccine Twinrix Junior followed by Twinrix (adult):
Resources
This article was provided by U.S. Centers for Disease Control and Prevention. |
|||||||||||||||||||||||||||||||